Abstract: The present invention relates to a pharmaceutically acceptable salt of a sphingosine-1-phosphate receptor agonist and a crystalline form thereof, and more specifically, to a potassium salt or methanesulfonate of 1-[1-chloro-6-(3-chloro-1-isopropyl-1H-indazol-5-ylmethoxy)-3,4-dihydro-naphthalen-2-ylmethyl]-piperidine-4-carboxylic acid of formula 1, and a crystalline form thereof.
| # | Name | Date |
|---|---|---|
| 1 | 202317068619-STATEMENT OF UNDERTAKING (FORM 3) [12-10-2023(online)].pdf | 2023-10-12 |
| 2 | 202317068619-REQUEST FOR EXAMINATION (FORM-18) [12-10-2023(online)].pdf | 2023-10-12 |
| 3 | 202317068619-POWER OF AUTHORITY [12-10-2023(online)].pdf | 2023-10-12 |
| 4 | 202317068619-FORM 18 [12-10-2023(online)].pdf | 2023-10-12 |
| 5 | 202317068619-FORM 1 [12-10-2023(online)].pdf | 2023-10-12 |
| 6 | 202317068619-DRAWINGS [12-10-2023(online)].pdf | 2023-10-12 |
| 7 | 202317068619-DECLARATION OF INVENTORSHIP (FORM 5) [12-10-2023(online)].pdf | 2023-10-12 |
| 8 | 202317068619-COMPLETE SPECIFICATION [12-10-2023(online)].pdf | 2023-10-12 |
| 9 | 202317068619-Proof of Right [12-04-2024(online)].pdf | 2024-04-12 |
| 10 | 202317068619-FORM 3 [12-04-2024(online)].pdf | 2024-04-12 |